Adheris Health Ltd (AHE)

Currency in AUD
0.022
0.000(0.00%)
Closed·
AHE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.0200.022
52 wk Range
0.0180.190
Key Statistics
Bid/Ask
0.02 / 0.022
Prev. Close
0.022
Open
0.022
Day's Range
0.02-0.022
52 wk Range
0.018-0.19
Volume
1.33M
Average Volume (3m)
1.26M
1-Year Change
-88.1081%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AHE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.190
Upside
+763.64%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low revenue valuation multiple

Adheris Health Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Adheris Health Ltd Company Profile

Adheris Health Limited, together with its subsidiaries, provides pharmacy-driven patient engagement solutions in Australia, the United States, and the United Kingdom. The company offers THRiV, an omni-channel platform which provides pharmacy-driven patient and pharmacist engagement solutions to improve medication management. The company was formerly known as MedAdvisor Limited and changed its anme to Adheris Health Limited in November 2025. The company was incorporated in 2010 and is based in Woburn, Massachusetts.

Adheris Health Ltd Earnings Call Summary for Q4/2025

  • Q4 2025: U.S. revenue down 34% YoY to $10.1M AUD; vaccine revenue up 52%; stock drops 2.53% to $0.077 AUD
  • FY25 guidance: Revenue $88M AUD, gross margin 60.8%, EBITDA loss $6.5M-$7.3M AUD; 15% revenue growth expected in FY26
  • Strategy shift: Reducing U.S. sales team, restructuring account management; launching new patient engagement platform in Q2 FY26
  • Challenges: U.S. pharmacy market disruptions, financial pressure on major chains impacting partnerships and revenue
  • Outlook: Exploring potential U.S. business divestment; nearing cash breakeven, contingent on revenue growth
Last Updated: 07/31/2025, 09:24 AM
Read Full Transcript

Compare AHE to Peers and Sector

Metrics to compare
AHE
Peers
Sector
Relationship
P/E Ratio
−0.2x−4.3x−0.6x
PEG Ratio
0.000.020.00
Price/Book
13.4x2.1x2.6x
Price / LTM Sales
0.2x3.9x3.4x
Upside (Analyst Target)
-81.8%44.9%
Fair Value Upside
Unlock13.9%6.7%Unlock

Analyst Ratings

0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 0.190
(+763.64% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Oct 21, 2025
EPS / Forecast
-- / --
Revenue / Forecast
9.60M / --
EPS Revisions
Last 90 days

AHE Income Statement

FAQ

What Is the Adheris Health (AHE) Stock Price Today?

The Adheris Health stock price today is 0.022

What Stock Exchange Does Adheris Health Trade On?

Adheris Health is listed and trades on the Sydney Stock Exchange stock exchange.

What Is the Stock Symbol for Adheris Health?

The stock symbol for Adheris Health is "AHE."

What Is the Adheris Health Market Cap?

As of today, Adheris Health market cap is 14.00M.

What Is Adheris Health's Earnings Per Share (TTM)?

The Adheris Health EPS (TTM) is -0.11.

When Is the Next Adheris Health Earnings Date?

Adheris Health will release its next earnings report on Feb 25, 2026.

From a Technical Analysis Perspective, Is AHE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Adheris Health Stock Split?

Adheris Health has split 2 times.

What is the current trading status of Adheris Health (AHE)?

As of Jan 31, 2026, Adheris Health (AHE) is trading at a price of 0.022, with a previous close of 0.022. The stock has fluctuated within a day range of 0.020 to 0.022, while its 52-week range spans from 0.018 to 0.190.

What Is Adheris Health (AHE) Price Target According to Analysts?

The average 12-month price target for Adheris Health is AUD0.190, with a high estimate of AUD0.19 and a low estimate of AUD0.19. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +763.64% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.